Does a GLP-1 Cause Muscle Loss?

The short version: weight loss of any kind takes some lean mass with it. The useful questions are how much, and what can be done about it.

GLP-1 medications do reduce lean mass along with fat, as nearly all weight loss does. In the tirzepatide body composition substudy, roughly 75% of the weight lost was fat and roughly 25% was lean mass, a proportion that was similar in the placebo group.¹ Whether a given person loses clinically meaningful muscle depends on how fast they lose weight, how much protein they eat and whether they train.

What do the trials show?

The best-known body composition data come from a substudy of SURMOUNT-1, the tirzepatide obesity trial. Of the 2,539 participants, 160 had dual-energy X-ray absorptiometry (DXA) scans at baseline and at week 72. Participants were 73% female with a mean body mass index of 38.0.¹

Lean mass fell more in absolute terms on tirzepatide because far more weight was lost. As a share of the weight lost, the split was about 75% fat and 25% lean mass in both groups.¹ The substudy was small relative to the full trial, the subgroup analyses were post hoc, and the authors include employees of the drug's manufacturer, which is worth knowing when reading the results.¹

Is lean mass the same as muscle?

No. DXA reports fat mass, bone mineral and lean mass. Lean mass includes skeletal muscle but also water, organs and connective tissue, so a drop in lean mass is not the same as an equal drop in muscle. The question of how medically induced weight loss affects skeletal muscle, as opposed to lean mass overall, is the subject of a 2024 commentary in The Lancet Diabetes and Endocrinology.²

That distinction matters for the headline numbers circulating online. A figure for lean mass loss is an upper bound on muscle loss, and it says nothing by itself about whether a person is weaker or less able to function.

Does strength drop too?

Not necessarily. The SEMALEAN study followed 106 adults with obesity taking semaglutide 2.4 mg. Weight fell by about 13% at 12 months and fat mass by 18%. Lean mass dropped by about 3 kg in the first 7 months and then stabilised, while handgrip strength improved by 4.5 kg at 12 months.³ It was an observational study without a control group, so it cannot show why strength improved, but it shows that a lean mass decline and a strength decline are not the same thing.

Who has more reason to be careful?

People who start with less muscle have less margin, which includes older adults and anyone already weak or inactive. This is reasoning rather than a finding from the GLP-1 trials above. In the Villareal trial of 160 obese older adults, weight loss raised a specific concern: the authors framed the question as whether dieting might accelerate age-related loss of muscle and bone.⁴ A prescriber can weigh this when choosing a pace and a dose, and anyone with a history of low muscle mass or falls should raise it.

What does the research say about protecting muscle?

No trial in this article tested a protection plan for people on a GLP-1 specifically, so the following comes from weight loss research more broadly.

• Resistance training. In the Villareal randomized trial, older adults on a weight-management program lost about 9% of body weight in every exercise group. Lean mass fell about 2% with resistance training and 3% with combined training, compared with 5% with aerobic exercise alone. Strength rose about 19% with resistance training.⁴
• Protein. A meta-analysis of 24 randomized trials (1,063 people) found that higher-protein, energy-restricted diets mitigated the loss of fat-free mass by a modest 0.43 kg compared with standard-protein diets.⁵ The effect was small, and the diets lasted about 12 weeks on average.

Nothing here establishes an ideal protein target for a person taking a GLP-1. A prescriber or registered dietitian can set one that fits kidney function, age and activity. People with kidney disease in particular should not raise protein without clinical guidance.

What this means for someone considering a GLP-1

The data do not say GLP-1 drugs are a muscle-wasting problem, and they do not say the issue is imaginary. Lean mass falls with weight loss, strength measures in the studies above held or improved, and the most reliable counter-measure on offer is a training habit rather than a product. For the broader safety picture, see our guide to GLP-1 side effects, and for how the drug itself acts, what tirzepatide is.

Quick questions

Does Ozempic or Mounjaro cause muscle loss?

They reduce lean mass along with fat, as weight loss in general does. In the tirzepatide substudy, about 25% of weight lost was lean mass, similar to placebo.{LOOK}

Is lean mass loss the same as muscle loss?

No. Lean mass also includes water, organs and bone, so a drop in lean mass overstates muscle loss.{PRADO}

Can resistance training reduce muscle loss while losing weight?

In a randomized trial of 160 dieting older adults, lean mass fell less with resistance training than with aerobic exercise alone.{VILL}

Does eating more protein help?

A meta-analysis of 24 trials found a modest benefit in preserving fat-free mass on higher-protein diets.{WYCH} Ask a clinician or dietitian for a target that fits your health.

More briefs

• Compounded GLP-1s Explained: What They Are and What to Ask
• GLP-1 Side Effects: What Is Common, What Is Serious
• What Is Tirzepatide? How the Dual GIP and GLP-1 Medication Works